
Each year, nearly 270,000 new cases of prostate cancer are diagnosed in the United States, and prostate cancer continues to be the second leading cause of cancer-related mortality in American males.1 Surgical treatment of localized prostate cancer remains a key component in the treatment pathway for these patients. Historically, although laparoscopic radical prostatectomy was investigated, it was not widely adopted for multiple reasons, including a challenging learning curve and no significant difference in operating time.2 Open radical prostatectomy (ORP) remained the predominant method for treatment of localized prostate cancer until the early 2000s, when the introduction of the da Vinci Surgical platform ushered in the era of robotics.3
Over the course of the past 20 years, various techniques, outcomes, and continued improvements in robot-assisted laparoscopic radical prostatectomy (RALP) have continued to emerge. More recently, the introduction of the da Vinci Single Port (SP) robot has provided further room for innovation and enhancement of the RALP technique.3 Concerns about cost, compared with traditional open radical prostatectomy, seem to have dissipated as several reports have consistently reported RALP to be a cost-effective treatment alternative to its open counterpart.4 In this article, we briefly summarize a history of the RALP, its outcomes, and future directions.
Although randomized controlled trials in surgical care are difficult to perform due to their invasive nature, there is some high-level evidence showing an overall favorable profile for RALP compared with ORP. In a phase 3 randomized clinical trial comparing RALP with ORP in Australia, investigators randomized men with localized prostate cancer in a 1:1 ratio to RALP or ORP respectively.5 Primary outcomes included sexual function measured by the International Index of Erectile Function (IIEF), urinary function measured by the Expanded Prostate Cancer Index (EPIC), and oncologic outcomes including biochemical recurrence (BCR).